Enanta Pharmaceuticals (ENTA) Current Deferred Revenue (2012 - 2014)

Enanta Pharmaceuticals has reported Current Deferred Revenue for 3 years, with the latest figure at $51000.0 in Q1 2014.

• For the quarter ending Q1 2014, Current Deferred Revenue fell 55.65% year-over-year to $51000.0; the trailing twelve-month figure through Mar 2014 stood at $51000.0 (down 55.65% YoY), and the FY2013 full-year result was $10000.0, down 41.18% from the prior year.
• Current Deferred Revenue for Q1 2014 stood at $51000.0, up from $5000.0 in the prior quarter.
• The five-year high for Current Deferred Revenue was $115000.0 in Q1 2013, with the low at $5000.0 in Q4 2013.
• Historically, Current Deferred Revenue has averaged $39600.0 across 3 years, with a median of $17000.0 in 2012.
• Annual changes were most pronounced in 2013 — Current Deferred Revenue plunged 41.18% — and 2014, when it sank 55.65%.
• Enanta Pharmaceuticals' Current Deferred Revenue stood at $17000.0 in 2012, then plunged by 70.59% to $5000.0 in 2013, then surged by 920.0% to $51000.0 in 2014.
• The last three Current Deferred Revenue figures came in at $51000.0 (Q1 2014), $5000.0 (Q4 2013), and $10000.0 (Q3 2013), per Business Quant data.